论文部分内容阅读
目的探讨辛伐他汀在治疗女性糖尿病伴高脂血症及骨质疏松症中的临床应用价值。方法按随机数字表法将84例患者随机分为研究组和对照组各42例,其中研究组患者在常规治疗的基础上给予辛伐他汀治疗,对照组患者在常规治疗的基础上给予非诺贝特治疗,比较2组患者治疗前后的血清骨钙素(BGP)、钙(Ca)、磷(P)、碱性磷酸酶(ALP)水平及骨密度(BMD)。结果 2组患者在治疗前血清Ca、P、ALP、BGP及L2～4BMD、股骨颈BMD比较均无统计学差异(P均>0.05);治疗后,对照组上述各指标与治疗前比较均无统计学差异(P均>0.05),研究组患者ALP、BGP、L2～4BMD及股骨颈BMD等指标与治疗前比较差异均有统计学意义(P均<0.05),且与对照组治疗后相应指标比较差异亦有统计学意义(P均<0.05)。结论辛伐他汀治疗女性糖尿病伴高脂血症及骨质疏松症,既可有效降脂,又能促进骨细胞增殖,抗骨吸收,促进成骨细胞产生BGP,从而预防和治疗骨质疏松,具有重要的临床应用价值。
Objective To investigate the clinical value of simvastatin in the treatment of female diabetes with hyperlipidemia and osteoporosis. Methods According to the random number table method, 84 patients were randomly divided into study group and control group, with 42 cases in each group. The study group was given simvastatin on the basis of routine treatment and the control group was given fenofibrate Fibrate, calcium, phosphorus, alkaline phosphatase (ALP) and bone mineral density (BMD) in two groups before and after treatment. Results There was no significant difference in serum Ca, P, ALP, BGP, L2 ~ 4BMD and femoral neck BMD between the two groups before treatment (all P> 0.05). After treatment, the above indexes of the control group were all lower than those before treatment (P> 0.05). The ALP, BGP, L2 ~ 4BMD and femoral neck BMD in the study group were significantly different from those before treatment (all P <0.05), and were significantly higher than those in the control group after treatment There was also a statistically significant difference between the indexes (all P <0.05). Conclusion Simvastatin treatment of female patients with diabetes mellitus and hyperlipidemia and osteoporosis can not only reduce lipid effectively, but also promote osteoblast proliferation, anti-bone resorption and promote osteoblasts to produce BGP, so as to prevent and treat osteoporosis, Has important clinical value.